Trial Profile
Viral suppression in Cerebrospinal Fluid in HIV-1 infected patients receiving Ritonavir-boosted Atazanavir plus lamivudine dual theraphy. SCALA study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Feb 2019
Price :
$35
*
At a glance
- Drugs Atazanavir (Primary) ; Lamivudine (Primary) ; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms SCALA
- 14 Feb 2019 Status changed from recruiting to completed.
- 10 Jul 2014 New trial record